Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christodoulos Papadopoulos

Showing results (71-80 of 127) with videos related to

Pageof 13
Sort By:
Expert Opinion on Pharmacotherapy|January 29, 2024
Effectively addressing cardiovascular risk in people with metabolic-dysfunction associated fatty liver disease: not yet ready for prime time!Theocharis Koufakis, Djordje S Popovic, Christodoulos Papadopoulos, et al.
The American Journal of Cardiology|September 7, 2020
Meta-analysis Assessing the Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Left Ventricular Mass in Patients With Type 2 Diabetes MellitusDimitrios Patoulias, Christodoulos Papadopoulos, Alexandra Katsimardou, et al.
Current Vascular Pharmacology|April 10, 2019
Pharmacological Management of Diabetic NephropathyVasilios Papademetriou, Sofia Alataki, Konstantinos Stavropoulos, et al.
Journal of Cardiovascular Development and Disease|June 25, 2026
Prognostic Value of Right Ventricular Performance and Left Atrial Mechanical Efficiency in Paroxysmal Atrial FibrillationAristi Boulmpou, Efstathios Pagourelias, Georgios Zormpas, et al.
Medicina (Kaunas, Lithuania)|September 23, 2022
Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational StudyDimitrios Patoulias, Christodoulos Papadopoulos, Ioanna Zografou, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|February 15, 2020
Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodium-glucose co-transporter-2 inhibitorsDimitrios Patoulias, Christodoulos Papadopoulos, Konstantinos Stavropoulos, et al.
The American Journal of Cardiology|November 19, 2021
Updated Meta-Analysis Evaluating the Beneficial Effects of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Heart FailureDimitrios Patoulias, Christodoulos Papadopoulos, George Kassimis, et al.
The American Journal of Cardiology|November 19, 2021
Meta-Analysis of Dedicated Heart Failure Trials Evaluating the Effect of Sacubitril/Valsartan on Major Cardiac Rhythm DisordersDimitrios Patoulias, Christodoulos Papadopoulos, Maria Toumpourleka, et al.
The American Journal of Cardiology|December 3, 2021
Meta-Analysis Addressing the Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Flow-Mediated Dilation in Patients With Type 2 Diabetes MellitusDimitrios Patoulias, Christodoulos Papadopoulos, George Kassimis, et al.
Current Pharmaceutical Design|March 12, 2019
Mineralocorticoid Receptor Antagonists in Primary AldosteronismKonstantinos Stavropoulos, Christodoulos Papadopoulos, Konstantinos Koutsampasopoulos, et al.
Pageof 13

Showing results (71-80 of 127) with videos related to

Sort By:
Pageof 13
Expert Opinion on Pharmacotherapy|January 29, 2024
Effectively addressing cardiovascular risk in people with metabolic-dysfunction associated fatty liver disease: not yet ready for prime time!Theocharis Koufakis, Djordje S Popovic, Christodoulos Papadopoulos, et al.
The American Journal of Cardiology|September 7, 2020
Meta-analysis Assessing the Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Left Ventricular Mass in Patients With Type 2 Diabetes MellitusDimitrios Patoulias, Christodoulos Papadopoulos, Alexandra Katsimardou, et al.
Current Vascular Pharmacology|April 10, 2019
Pharmacological Management of Diabetic NephropathyVasilios Papademetriou, Sofia Alataki, Konstantinos Stavropoulos, et al.
Journal of Cardiovascular Development and Disease|June 25, 2026
Prognostic Value of Right Ventricular Performance and Left Atrial Mechanical Efficiency in Paroxysmal Atrial FibrillationAristi Boulmpou, Efstathios Pagourelias, Georgios Zormpas, et al.
Medicina (Kaunas, Lithuania)|September 23, 2022
Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational StudyDimitrios Patoulias, Christodoulos Papadopoulos, Ioanna Zografou, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|February 15, 2020
Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodium-glucose co-transporter-2 inhibitorsDimitrios Patoulias, Christodoulos Papadopoulos, Konstantinos Stavropoulos, et al.
The American Journal of Cardiology|November 19, 2021
Updated Meta-Analysis Evaluating the Beneficial Effects of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Heart FailureDimitrios Patoulias, Christodoulos Papadopoulos, George Kassimis, et al.
The American Journal of Cardiology|November 19, 2021
Meta-Analysis of Dedicated Heart Failure Trials Evaluating the Effect of Sacubitril/Valsartan on Major Cardiac Rhythm DisordersDimitrios Patoulias, Christodoulos Papadopoulos, Maria Toumpourleka, et al.
The American Journal of Cardiology|December 3, 2021
Meta-Analysis Addressing the Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Flow-Mediated Dilation in Patients With Type 2 Diabetes MellitusDimitrios Patoulias, Christodoulos Papadopoulos, George Kassimis, et al.
Current Pharmaceutical Design|March 12, 2019
Mineralocorticoid Receptor Antagonists in Primary AldosteronismKonstantinos Stavropoulos, Christodoulos Papadopoulos, Konstantinos Koutsampasopoulos, et al.
Pageof 13